Thus, at the individual patient level, across multiple cases, RBM10 inactivation was associated with decreased initial EGFR TKI sensitivity, relatively early clinical progression, and a decreased pathological tumor response in EGFR-mutant LA. This evidence concerns the gene EGFR and neoplasm.